ZLDPF - Zealand Pharma: Weight Loss Drug Petrelintide Is Not A 'Me Too' Advancement

2024-06-24 13:05:06 ET

Summary

• Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose.
• The global obesity market could reach $77 billion in 2030.
• Survodutide, dapiglutide, and ZP6590 are other drugs being advanced for the treatment of patients with obesity, offering an alternative to GLP-1 drugs.
• Zealand's cash position of $561,124,200 as of the end of Q1 of 2024 shows enough cash to fund its operations into 2027.

The last time I wrote about Zealand Pharma A/S ( ZLDPF ), it was in a Seeking Alpha article entitled " Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment. " I discussed how that it was advancing three drugs for the huge obesity market, but primarily I went over the dual aspect that survodutide could be used for both the treatment of patients with MASH [formerly known as NASH] and weight loss....

For further details see: